Research programme: breast cancer therapeutics - Theraclone Sciences

Drug Profile

Research programme: breast cancer therapeutics - Theraclone Sciences

Latest Information Update: 05 May 2014

Price : $50

At a glance

  • Originator Theraclone Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 24 Apr 2014 Preclinical in Breast cancer (triple negative and endocrine treatment resistant) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top